Midodrine to Facilitate Guideline-Directed Medical Therapy in Heart Failure with Reduced Ejection Fraction: A Promising Breakthrough or Just a False Hope?

Abstract

Guideline-directed medical therapy (GDMT) is the foundation of managing heart failure with reduced ejection fraction (HFrEF). However, hypotension often limits its implementation, preventing optimal medication titration. Midodrine, an alpha-1 adrenergic agonist, has been explored as a potential option to facilitate the initiation and continuation of GDMT. Our review assesses the role of midodrine in the management of HFrEF, evaluating its benefits, risks, and clinical applicability. While emerging evidence suggests midodrine may help stabilize blood pressure and enable the optimization of GDMT in select patients with refractory hypotension, concerns remain regarding its long-term safety, potential for increased afterload, and associated mortality risks. Some observational studies indicate improved adherence to GDMT, but conflicting findings on patient outcomes, including increased mortality, highlight concerns. Still, the therapeutic promise of midodrine in HFrEF is undeniably compelling, offering the exciting possibility of transforming HFrEF management. The current evidence is low due to reliance on observational studies. Robust, large-scale randomized controlled trials are urgently needed to confirm its safety, efficacy, and precise patient selection criteria. The ongoing MIDOH-HF-P trial, results of which are anticipated in 2026, could provide vital insights into short-term benefits with GDMT. However, until robust evidence emerges and additional data are available, clinicians must exercise extreme caution when considering its off-label use.